Literature DB >> 23608883

Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.

D Zamarin1, S M Devlin, M E Arcila, H Landau, A Lesokhin, N Lendvai, D J Chung, D Chimento, J Weltz, D Babu, S Giralt, H Hassoun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23608883     DOI： 10.1038/leu.2013.126

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.

Authors:  Vien Phan; Tomoki Ito; Muneo Inaba; Yoshiko Azuma; Kayoko Kibata; Noriko Inagaki-Katashiba; Akihiro Tanaka; Atsushi Satake; Shosaku Nomura
Journal:  Blood Adv       Date:  2020-08-11

2.  Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Authors:  M A Dimopoulos; A S Swern; J S Li; M Hussein; L Weiss; Y Nagarwala; R Baz
Journal:  Blood Cancer J       Date:  2014-11-07       Impact factor: 11.037

3.  Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.

Authors:  P Ravi; S Kumar; W Gonsalves; F Buadi; M Q Lacy; R S Go; A Dispenzieri; P Kapoor; J A Lust; D Dingli; Y Lin; S J Russell; N Leung; M A Gertz; R A Kyle; P L Bergsagel; S V Rajkumar
Journal:  Blood Cancer J       Date:  2017-06-16       Impact factor: 11.037

4.  Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.

Authors:  Rouslan Kotchetkov; Esther Masih-Khan; Chia-Min Chu; Eshetu G Atenafu; Christine Chen; Vishal Kukreti; Suzanne Trudel; Rodger Tiedemann; Donna E Reece
Journal:  Cancer Med       Date:  2016-11-18       Impact factor: 4.452

5.  Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma.

Authors:  Shuji Ozaki; Takeshi Harada; Hikaru Yagi; Etsuko Sekimoto; Hironobu Shibata; Toshio Shigekiyo; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Kumiko Kagawa; Masahiro Abe
Journal:  Cancers (Basel)       Date:  2019-12-18       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.